169 results on '"Brooun, Alexei"'
Search Results
2. The pharmacologic and toxicologic characterization of the potent and selective KRAS G12D inhibitors ERAS-4693 and ERAS-5024
3. Development of a robust crystallization platform for immune receptor TREM2 using a crystallization chaperone strategy
4. Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation
5. A streamlined, automated workflow to screen and triage large numbers of baculoviruses for protein expression
6. Identification, structural, and biophysical characterization of a positive modulator of human Kv3.1 channels
7. Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors
8. Data from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
9. Supplementary Figures from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
10. Supplementary Data S2 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
11. Supplementary Methods from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
12. The Primary Structures of the Archaeon Halobacterium salinarium Blue Light Receptor Sensory Rhodopsin II and its Transducer, a Methyl-Accepting Protein
13. Signal Transduction in the Archaeon Halobacterium salinarium is Processed through Three Subfamilies of 13 Soluble and Membrane-Bound Transducer Proteins
14. Identification and structural and biophysical characterization of a positive modulator of human Kv3.1 channels.
15. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
16. Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists
17. SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
18. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
19. Supplement to: Acquired resistance to crizotinib from a mutation in CD74-ROS1.
20. Abstract 1160: SAM competitive PRMT5 inhibitor PF06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance
21. Structural Basis of Guanine Nucleotide Exchange Mediated by the T-Cell Essential Vav1
22. Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design
23. Three-dimensional Structure of the EphB2 Receptor in Complex with an Antagonistic Peptide Reveals a Novel Mode of Inhibition
24. Profiling of membrane protein variants in a baculovirus system by coupling cell-surface detection with small-scale parallel expression
25. Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
26. Structural and Biophysical Characterization of the EphB4·EphrinB2 Protein-Protein Interaction and Receptor Specificity
27. Structure and Thermodynamic Characterization of the EphB4/Ephrin-B2 Antagonist Peptide Complex Reveals the Determinants for Receptor Specificity
28. Identification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein–protein interaction
29. Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)
30. Structural and Biophysical Characterization of XIAP BIR3 G306E Mutant: Insights in Protein Dynamics and Application for Fragment-Based Drug Design
31. An archaeal aerotaxis transducer combines subunit I core structures of eukaryotic cytochrome c oxidase and eubacterial methyl-accepting chemotaxis proteins
32. Primary structure and functional analysis of the soluble transducer protein HtrXI in the archaeon Halobacterium salinarium
33. HIV-1 Preintegration Complexes Preferentially Integrate into Longer Target DNA Molecules in Solution as Detected by a Sensitive, Polymerase Chain Reaction-based Integration Assay
34. Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).
35. Purification and ligand binding of EmrR, a regulator of a multidrug transporter
36. Expression and fast-flow purification of a polyhistidine-tagged myoglobin-like aerotaxis transducer
37. Sensory rhodopsin II transducer HtrII is also responsible for serine chemotaxis in the archaeon Halobacterium salinarum
38. Reviving B-Factors: Activating ALK Mutations Increase Protein Dynamics of the Unphosphorylated Kinase
39. Abstract 4857: Discovery of PF-06855800, a SAM competitive PRMT5 inhibitor with potent antitumor activity
40. Reviving B-Factors: Retrospective Normalized B-Factor Analysis of c-ros Oncogene 1 Receptor Tyrosine Kinase and Anaplastic Lymphoma Kinase L1196M with Crizotinib and Lorlatinib
41. Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
42. Conserved RNA-binding specificity of polycomb repressive complex 2 is achieved by dispersed amino acid patches in EZH2
43. Author response: Conserved RNA-binding specificity of polycomb repressive complex 2 is achieved by dispersed amino acid patches in EZH2
44. Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
45. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance
46. Resensitization to Crizotinib by the LorlatinibALKResistance Mutation L1198F
47. Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5...
48. Comparison of a High-Throughput Mass Spectrometry Method and Radioactive Filter Binding to Assay the Protein Methyltransferase PRMT5
49. Conserved RNA-binding specificity of polycomb repressive complex 2 is achieved by dispersed amino acid patches in EZH2.
50. Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.